Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
for Relapsing Multiple Sclerosis
36 locations incl. Birmingham
Sponsor: TG Therapeutics, Inc.
Sex: All·Age: 18 - 65
Code: NCT05877963·Phase 3·Recruiting